BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25778469)

  • 21. Genetic variants of nucleotide excision repair genes are associated with DNA damage in coke oven workers.
    Wang F; He Y; Guo H; Li J; Yang Y; Wu Z; Zheng H; Wu T
    Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):211-8. PubMed ID: 20056640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer.
    Dong Y; Liu JW; Gao YJ; Zhou T; Chen YM
    Genet Mol Res; 2015 May; 14(2):5390-8. PubMed ID: 26125734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
    Saldivar JS; Lu KH; Liang D; Gu J; Huang M; Vlastos AT; Follen M; Wu X
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S223-9. PubMed ID: 17825393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.
    Gu J; Zhao H; Dinney CP; Zhu Y; Leibovici D; Bermejo CE; Grossman HB; Wu X
    Clin Cancer Res; 2005 Feb; 11(4):1408-15. PubMed ID: 15746040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls.
    Slyskova J; Naccarati A; Pardini B; Polakova V; Vodickova L; Smerhovsky Z; Levy M; Lipska L; Liska V; Vodicka P
    Mutagenesis; 2012 Mar; 27(2):225-32. PubMed ID: 22294771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
    Ye F; Liu Z; Tan A; Liao M; Mo Z; Yang X
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):733-40. PubMed ID: 23299794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic variation in the nucleotide excision repair pathway and colorectal cancer risk.
    Berndt SI; Platz EA; Fallin MD; Thuita LW; Hoffman SC; Helzlsouer KJ
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2263-9. PubMed ID: 17119055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
    Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
    J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
    Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput RNAi screening of human kinases identifies predictors of clinical outcome in colorectal cancer patients treated with oxaliplatin.
    Lin M; Zhang Y; Li A; Tang E; Peng J; Tang W; Zhang Y; Lu L; Xiao Y; Wei Q; Yin L; Li H
    Oncotarget; 2015 Jun; 6(18):16774-85. PubMed ID: 25904054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population.
    Liu Y; Chen H; Chen L; Hu C
    Hepatogastroenterology; 2012 Jun; 59(116):977-80. PubMed ID: 22580644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.
    Stoehlmacher J; Ghaderi V; Iobal S; Groshen S; Tsao-Wei D; Park D; Lenz HJ
    Anticancer Res; 2001; 21(4B):3075-9. PubMed ID: 11712813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.
    Kweekel DM; Gelderblom H; Guchelaar HJ
    Cancer Treat Rev; 2005 Apr; 31(2):90-105. PubMed ID: 15847979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
    Liu YP; Ling Y; Qi QF; Zhang YP; Zhang CS; Zhu CT; Wang MH; Pan YD
    Mol Med Rep; 2013 Jun; 7(6):1904-11. PubMed ID: 23604281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients].
    Chen YM; Wu XL; Zhang LW; Xu X; Liu JW
    Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):501-5. PubMed ID: 22967467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
    Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei DD; Groshen S; Lenz HJ
    Cancer Res; 2001 Dec; 61(24):8654-8. PubMed ID: 11751380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?
    Madbouly KM; Hussein AM; Zeid A
    Dis Colon Rectum; 2013 May; 56(5):577-85. PubMed ID: 23575396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.